Ignota Labs secures Sanofi’s prestigious iDEA-Tech Award

Advancing predictive toxicology: overcoming hurdles and shaping the future

Maddyness: An interview with our CEO Sam Windsor

Ignota Labs In-Licenses First Proprietary Asset: Pioneering PDE9A Inhibitor Set to Transform Multi-Action Therapeutics

PharmaPhorum: Why drugs fail

AI for Pharma Growth: Rescuing failed drug projects

Ignota Labs accepted for the 2024 cohort of TechBio Boost

Improved Detection of Drug-Induced Liver Injury